Latest Industry Insights

To learn more about Kai – an AI-powered personal guide and companion – and the potential benefits of using AI as a wellness tool for mental health, Technology Networks spoke to Alex Frenkel.

Delix Therapeutics is developing non-hallucinogenic psychedelics for use as at-home medications for mental health conditions. To find out more, we spoke to the CEO, Mark Rus.

Beckley Psytech recently announced that they have dosed the first healthy volunteers in their Phase I trial of an intranasally delivered formulation of 5-MeO-DMT, named BPL-003. To find out more about their trial approach and wider research into 5-MeO-DMT, we spoke to Beckley’s chief scientific offer, Dr. Steve Wooding.

Blackrock Neurotech, a leader in brain-computer interface (BCI) device design, recently has announced a collaboration with Venice, CA-based software developer AE Studio. To find out more, we spoke to Evan Coopersmith, AE Studio’s executive vice-president of data science.

To find out more about how early-stage funding could improve longevity research, we had the pleasure of speaking to Garri Zmudze, executive director of the Longevity Science Foundation.

Research is advancing exciting areas of science at an unprecedented pace, but the disposable materials, powered equipment and shipping associated with experiments, sample storage and transport of reagents contribute to high energy consumption and significant waste. How are researchers bringing sustainability to scientific discovery?

A new study has compared the effects of varied doses of psilocybin and LSD for the first time. These two popular psychedelics have been of increasing interest in clinical research. Technology Networks caught up with Rob Barrow, CEO of MindMed, to discuss the findings in more detail and explore pressing issues around blinding in psychedelic drug development.

Dr. Christian Landles explains why it is so challenging to develop therapeutics for rare diseases such as HD, and discusses the potential of approaches that target mutant huntingtin protein to improve treatment options for HD patients.

Dr. Christian Landles highlights some of the progress made in recent years to improve our understanding of HD and its drivers.

Psychedelic-assisted psychotherapy (PAP) is under investigation for its potential in treating psychiatric conditions. A recent paper, published by academics Agnieszka Sekula and Dr. Prash Puspanathan, outlined how virtual reality (VR) might be incorporated into aspects of the PAP process.